Drugs / Fosfomycin trometamol
Fosfomycin trometamol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06822751 | Jul 2026 → Oct 2029 expected | cystitis, prostatitis, urinary tract infection | University Hospital, Rouen | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02639520 Comparator | Dec 2015 → Jun 2017 | urinary tract infection | Bionorica SE | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosfomycin trometamol | “Study of the efficacy and safety of Fosfomycin trometamol as a 14-day treatment using a 3 g sachet every 2 days for 14 days for the treatment of male urinary tract infections...” NCT06822751 ↗ |
| Known as | FOSFOMYCINE ARROW ADULTS | “Single-Arm The treatment studied is fosfomycin trometamol (FT): FOSFOMYCINE ARROW ADULTS 3 g, granule for drinkable solution in sachet.” NCT06822751 ↗ |
| Known as | MONURIL | “In response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®).” NCT06822751 ↗ |
| Route | Oral | “It comes in a sachet of 3 g of granules for oral solution (orange flavour).” NCT06822751 ↗ |